The Next Drugs:
An Atlantic Policy Update on Biosimilars

June 7, 2017
Washington, DC

Biosimilars – and the policy and regulatory debates surrounding these complex large-molecule drugs – continue to be a hot topic in Washington.  A patent case in front of the Supreme Court and laws making their way through Congress have the potential to change the market and industry.

The Atlantic convened key stakeholders to discuss the state of and future for biosimilars. What impact will ongoing regulatory and policy considerations have? What can stakeholders expect when it comes to patents and exclusivity? And what effect will the priorities of leadership in Congress and the Administration have on the industry across the next few years?



Watch full session videos

Presented by

Atlantic Live

Speakers

Agenda

  • Wednesday, June 07
  • 8:20 a.m.WelcomeEmily Akhtarzandi, Managing Director, AtlanticLIVE
    Chester “Chip” Davis, Jr.*, President and CEO, Association for Accessible Medicines
  • 8:30 a.m.The Role of CongressRepresentative Peter Welch (D-VT)
    With Steve Clemons, Washington Editor at Large, The Atlantic
  • 8:50 a.m.The Patent LandscapeBruce Artim, Senior Director, Federal Government Affairs, Eli Lilly and Company
    Courtenay Brinckerhoff, Partner, Foley & Lardner LLP
    Phil Nickson, Associate General Counsel, Intellectual Property, Momenta Pharmaceuticals
    With Olga Khazan, Staff Writer, The Atlantic
  • 9:20 a.m.Closing ThoughtsEmily Akhtarzandi, AtlanticLIVE

Underwriter

Also in This Series

Upcoming Events

  • Health Care

    The State of Care: Innovation & Access

    What is the balance between rewarding innovation and ensuring access to health discoveries?

  • Washington Ideas

    Now in its 10th year, The Atlantic's Washington Ideas will tackle the most consequential issues of our time with some of the nation's most important leaders from business, politics and culture.

  • Health Care

    The New Old Age

    How is getting older changing in America?